Antifungal Drugs: Heavy Focus on Therapeutics in Early

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Mar 13, 2017 at 6:00 AM 105

Antifungal Drugs: Heavy Focus on Therapeutics in Early Development - Technologies and Global Markets Report 2017-2021

Dublin, March 13, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Antifungal Drugs: Technologies and Global Markets" report to their offering. The aim of this report is to initially conduct a review of the antifungal drugs currently available, the issues facing the use of antifungal drugs and review some of the latest developments of new and innovative antifungal drugs, their technologies, and their intended clinical applications. The key objective was also to conduct and provide an analysis of the market value, growth rates, market shares, market development as well as examining the market dynamics and market factors influencing the growth and development of this market. This report also looks at the challenges and potential threats facing the industry, and the factors influencing the market shares of the major market suppliers as well as smaller indigenous manufactures in local markets. The emphasis of this report is to provide the reader with: A detailed analysis of the revenues and forecasts for the global antifungal drugs market with a further more detailed analysis and forecast of the revenues for the global market sub-divided by major market sub-segments by geographic region and finally by selected country. A detailed analysis of the global market share together with a further more detailed analysis of the market share by geographic regions and finally by selected country.

Report Includes

An overview of the global market for antifungal drugs.
Analyses of global market trends, with data from 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021.
Identification of new antifungal research, development, and drug applications.
Heavy focus on therapeutics in early development such as new molecular and biological entities from traditional pharmaceutical sources, naturally derived synthetic chemicals, and biological sources.
Information on over the counter (OTC) vs. prescription products.

Profiles of major players in the industry

Ferrer Internacional S.A.
Enzon Pharmaceuticals Inc.
Astellas Pharma Inc.
Galderma Pharma SA Galderma SA
Gilead Sciences Inc.
Glenmark Pharmaceuticals Limited
Sigma-Tau Pharma-ceuticals Inc.
TEVA Pharmaceuticals Industries Ltd.
Valeant Pharmaceuticals International Inc.
Dartmouth Pharmaceuticals.

Key Topics Covered: 1: Introduction - Introduction To The Report - Reasons For Doing This Study - Scope - Methodology 2: Executive Summary - Market Segmentation 3: Introduction To The Global Antifungal Drug Market - Scope Of Applications: Human Healthcare - Primary Fungal Infections - Opportunistic Fungal Infections - Human Fungal Infections - Selection Of Statistical Data On Fungal Infections - Fungal Infection Of The Nails - Risk Factors For Developing Fungal Infections - Fungal Species That Cause Infection In Humans 4: Common Environmental Fungi - Molds And The Human Issues Associated With Them - Why Environmental Mold Is A Unique Problem - Health Risks Due To Environment Fungi And Mold - Environmental Molds 5: Antifungal Agents - Antifungal Agents - Classification Of Anti Fungal Agents - Systemic Antifungal Drugs - Azoles - Echinocandins - Antimetabolite: Flucytosine (5-Fc) - Other Systemic Antifungal Agents - Topical Antifungal Drugs - Others 6: Summary: Global Market For Antifungal Drugs - Introduction - Market Revenue Analysis 7: North American Market For Antifungal Drugs - Regulatory And Legislative Requirements - Market Dynamics - Market Revenue Analysis - Market Share Analysis 8: European Market For Antifungal Drugs - Regulatory And Legisative Requirements: Europe - The Russian Federation - Market Dynamics - Market Revenue Analysis - Market Share Analysis 9: Asia-Pacific Market For Antifungal Drugs - Japan - China - India - South Korea - Market Dynamics - Market Revenue Analysis - Market Share Analysis 10: Latin America Market For Antifungal Drugs - Brazil - Argentina - Mexico - Market Dynamics - Market Revenue Analysis - Market Share Analysis 11: Middle East/Africa Market For Antifungal Drugs - Introduction - South Africa - Saudi Arabia - Market Dynamics - Market Revenue Analysis - Market Share Analysis 12: Company Profiles - Manufacturers Of Prescription Pharmaceuticals - Otc Antifungal Manufacturers - Pharmaceutical Otc Market - Alternative Otc Manufacturers - Major Alternative Otc Manufacturer Profiles 13: Appendixes 14: Government Regulatory Agencies And Professional Associations - Government Regulations - Food And Drug Administration (Fda) - Environmental Protection Agency (Epa) - United States Department Of Agriculture (Usda) - Food And Agricultural Organization Of The United Nations - Professional Associations For more information about this report visit http://www.researchandmarkets.com/research/vn...ngal_drugs

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Over the Counter (OTC) Drugs

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Consumer Debt Balloons to $18.56T Amid Economic Jitters

The Debt Tide Keeps Rising Alright, let’s dive calloused knuckles first into what's cooking with U.S. consumer debt these days. Shockwaves through the wallet world this past September—consumer debt surged to a jaw-dropping $18.56 trillion. That's a hefty climb of 2.9% year-over-year, and for anyone keeping score, it wasn't just about mortgages hiking up their pricey...

Gulliver Prep's New STEAM Complex to Transform Miami

Gulliver Prep Leads the Charge in Education Innovation Gulliver Preparatory School just dropped a bombshell in Miami—almost literally, with their shovels hitting the dirt for a new 95,000-square-foot STEAM complex. It's not some lip-service to educational buzzwords either. This project's part of 'The Next 100: The Centennial Campaign for Gulliver,' a mega drive to...

Day Out Snacks Brings Back Sold-Out Peppermint Bark

Spicing Up the Holidays with a Best-Seller Return You've got to love when a brand nails it in the holiday treat department, and Day Out Snacks is playing a winning hand by bringing back their Peppermint Bark protein balls. Here we are again, one year after they flew off the shelves like Santa spotted on Christmas Eve. And let me tell you, this re-release has the potential...

Huntsman Declares Q4 Dividend: $0.0875 Per Share

Huntsman Corporation Delivers Dividend Update So, here's the lowdown from Huntsman Corporation coming at us on a rather sleepy November morning in 2026. They've announced their fourth quarter dividend—a neat $0.0875 per share. Now, this isn’t exactly hitting us like a seismic shockwave, but every little drip counts when you're invested in NYSE:HUN, which is exactly...

Woolery & Co Boosts M&A Expertise with Debbie Wang

A New Power Player Joins Woolery & Co Let me tell you, every now and then a firm makes a move that absolutely oozes strategic brilliance, and this right here is one of those moments. Woolery & Co, a name that's been making waves in strategic advisory circles, has just added Debbie Wang to their lineup. If you're not familiar, she's fresh from Ropes & Gray LLP where she...

Insulin Delivery Devices: A Billion-Dollar Surge

When's the last time you saw a medical device market promising a $10 billion leap in under five years? Yeah, the insulin delivery devices market's got that kind of upside, projected to skyrocket from $16.92 billion in 2026 to a whopping $26.37 billion by 2031. That's a 9.3% annual growth rate. The numbers and the stakes are both staggering. Regional and Segment Leaders...

O-I Glass Faces Class Action: What Investors Must Know

The Unsettling News for O-I Glass Investors Let me dive right into this mess about O-I Glass, Inc. (NYSE:OI). If you're tangled up in their stock, you probably felt that 15.01% nosedive in your portfolio recently. That's no minor blip. On July 28, 2026, as stocks were virtually put through the shredder, O-I Glass announced they had to cut down their financial guidance for...

Lightwave Logic Delays Spur Legal Investigation

Lightwave Logic Faces Legal Hurdles There's trouble brewing for Lightwave Logic, Inc. (NASDAQ: LWLG) after its decision to push back volume production to 2028 stirred the pot. Shares took a nosedive, opening down by about 15% at $3.73, after the company revealed their foundry process and customer qualifications were dragging at a snail's pace. And as you might expect,...

RELEX Solutions: Dominating Supply Chain Assessments

Standing Tall in the Supply Chain Arena Every now and then, a company manages to stand out in a way that makes even the seasoned market watchers take notice. This time, it's RELEX Solutions grabbing the spotlight. They've been recognized as a Leader in four separate IDC MarketScape assessments for 2026. It's no small feat considering the crowded stage of supply chain...

BSR REIT's Q3 2026 Financials: Strategic Progress Made

BSR REIT Hits Strategic Milestones in Q3 Here's a bit of exciting news hitting us from BSR Real Estate Investment Trust. They've dropped their financial results for the third quarter of 2026. Packed with some solid gains, this quarter wasn't just about the numbers—it was about the moves they've been making underneath it all. So, let's break down what they're up to, and...